What is IMMX's current stock price?

IMMX (Immix Biopharma, Inc.) is currently trading at $8.78 with a market cap of $477.7M.

What sector is Immix Biopharma, Inc. in?

Immix Biopharma, Inc. (IMMX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IMMX a good stock to buy?

Analysts have a Buy consensus on IMMX with a price target of $17.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IMMX Immix Biopharma, Inc.

Healthcare

$8.78+1.27%ClosedMarket Cap: $477.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.98

P/S

0.00

EV/EBITDA

-11.22

DCF Value

$2.82

FCF Yield

-6.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-73.2%

ROA

-36.5%

ROIC

-42.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-10.1M	$—
Q4 null	$0.00	$-10.7M	$—
FY null	$0.00	$-29.4M	$—
Q3 null	$0.00	$-7.6M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$17.00

Target Range

$14.00 - $20.00

2 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-22

MizuhoOutperform

2026-03-30

HC Wainwright & Co.Buy

2026-03-30

CitizensMarket Outperform

2026-03-27

HC Wainwright & Co.Buy

2025-12-09

Trading Activity

Insider Trades

View All

CHANG NANCY Tdirector

SellThu Dec 11

Rachman Ilya Mdirector, officer: CEO and Chairman

BuyWed Dec 10

Morris Gabriel Sdirector, officer: CFO

SellWed Dec 10

Morris Gabriel Sdirector, officer: CFO

SellWed Dec 10

Morris Gabriel Sdirector, officer: CFO

BuyWed Dec 10

Latest News

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common StockGlobeNewsWire · Fri May 22

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.12

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Peers

TIL